Signing of definitive purchase agreement represents critical next step in completing previously announced acquisition Family Beginnings generated revenue of approximately $1.2 million and net income of approximately $0.2 million for the trailing 12-month period ended September 30, 2025. Safe Harbor Statement This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Comp ...

SARASOTA, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (“INVO” or the “Company”) (NASDAQ: IVF), a healthcare company focused on the fertility market, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 2,366,864 shares of common stock (or pre-funded warrants in-lieu thereof), together with warrants to purchase up to an aggregate 4,733,728 shares of common stock, in a private placement priced at-the-market under Nasdaq rule ...

Acquisition advances INVO’s national expansion strategy, enhances its clinical capabilities, and broadens access to innovative fertility care across the MidwestSARASOTA, Fla. and INDIANAPOLIS, Nov. 28, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced its intent to acquire Family Beginnings, P.C., a respecte ...

Core Viewpoint - INVO Fertility, Inc. will implement a 1-for-8 reverse stock split effective November 28, 2025, to enhance its stock price and maintain compliance with Nasdaq listing requirements [1][2]. Company Overview - INVO Fertility is a healthcare services company focused on the fertility market, particularly in expanding assisted reproductive technology (ART) care [3]. - The company's strategy includes building, acquiring, and operating fertility clinics, specifically "INVO Centers" that offer the intravaginal culture (IVC) procedure using the proprietary INVOcell medical device [3]. - INVO Fertility currently operates two INVO Centers and one IVF clinic in the United States and distributes the INVOcell technology to third-party fertility clinics [3]. - The IVC procedure is designed to provide a more natural, intimate, and cost-effective alternative to traditional IVF, with comparable results at a lower cost [3].

SARASOTA, Fla., Nov. 17, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility company focused on the establishment, acquisition and operation of fertility clinics and related businesses and technologies, today announced third quarter 2025 financial results. Q3 2025 Financial Highlights (all metrics compared to Q3 2024 unless otherwise noted) Revenue was $1,757,094, an increase of 23% compared to $1,433,151.Consolidated clinic revenue from th ...

Core Insights - INVO Fertility has announced a strategic partnership with Heidi Health to integrate an AI-powered scribe platform at its Wisconsin Fertility Institute, aimed at enhancing patient care and reducing administrative burdens for clinicians [1][3]. Company Overview - INVO Fertility is a healthcare services company focused on expanding access to assisted reproductive technology (ART) through the establishment, acquisition, and operation of fertility clinics [5]. - The company operates two INVO Centers in the U.S. and one IVF clinic, and it is engaged in the sale and distribution of its proprietary INVOcell technology, which allows fertilization and early embryo development to occur in vivo [5]. Technology Integration - The AI-powered tool from Heidi Health automates clinical documentation, allowing clinicians to spend less time on administrative tasks, thus reducing burnout and improving patient interaction [2][3]. - The integration of the AI scribe is expected to automate over two hours of daily administrative work for clinicians, significantly decreasing manual note-taking by up to 80% [3]. Patient Experience Enhancement - The partnership aims to elevate the patient experience at the Wisconsin clinic, ensuring that individuals feel supported throughout their treatment journey [4]. - The technology will enable specialists to focus more on patient care, building trust, and personalizing treatment plans [3][4].

Core Insights - INVO Fertility, Inc. will participate in the Lytham Partners Fall 2025 Investor Conference, hosting a webcast presentation and one-on-one meetings with investors on September 30, 2025 [1][2][3] Company Overview - INVO Fertility is a healthcare services company focused on expanding access to assisted reproductive technology (ART) through the establishment, acquisition, and operation of fertility clinics [4] - The company's primary strategy includes building and operating "INVO Centers" that offer the intravaginal culture (IVC) procedure using the proprietary INVOcell medical device, which allows fertilization and early embryo development to occur in vivo within the woman's body [4] - INVO Fertility currently operates two INVO Centers and one IVF clinic in the United States, and it also sells and distributes the INVOcell device to third-party fertility clinics [4] - The IVC procedure is designed to provide a more connected, intimate, and affordable experience compared to traditional ART treatments, potentially delivering comparable results at a lower cost than traditional IVF [4]

Core Viewpoint - INVO Fertility, Inc. reported its second quarter 2025 financial results, highlighting a focus on expanding fertility operations and innovative service offerings while navigating a net loss from continuing operations. Financial Highlights - Revenue for Q2 2025 was $1,863,654, marking a 1% increase from $1,836,597 in Q2 2024, setting a new quarterly record for the company [7] - Consolidated clinic revenue increased by 1% to $1,832,094 compared to $1,807,921 in the previous year [7] - Total revenue from all clinics, including consolidated and equity method clinics, rose by 2% to $2,188,893 from $2,141,229 [7] - Net loss from continuing operations was $(3.2) million, compared to $(2.2) million in the prior year [7] - Adjusted EBITDA was $(587,230), a decline from $(509,623) in Q2 2024 [7][15] Operational Highlights - The company completed the divestiture of a majority stake in NAYA on June 2, 2025, allowing both INVO Fertility and NAYA to focus on their respective operations [4] - INVO Fertility expanded its service offerings to include telehealth options and Platelet-Rich Plasma (PRP) therapy at its Wisconsin clinic, enhancing patient-centered care [5][7] - The Wisconsin Fertility Institute was recognized on Newsweek's List of America's Best Fertility Clinics for 2025 [7] - A new patent for a modified version of the INVOcell device was allowed, extending intellectual property protection through 2040 [7] Management Commentary - The CEO emphasized the commitment to growth and innovation in fertility operations, highlighting the expansion of services and training support for INVOcell technology [5] - The company aims to maintain an efficient and scalable operating structure while integrating complementary revenue-generating businesses and technologies [5]

Core Viewpoint - INVO Fertility, Inc. announced a 1-for-3 reverse stock split to comply with Nasdaq's minimum bid price requirement, effective July 21, 2025 [1][3]. Group 1: Reverse Stock Split Details - The reverse stock split will convert every 3 shares of common stock into 1 share, rounding up any fractional shares [2]. - Post-split, the company will have approximately 928,272 shares issued and outstanding, with authorized shares adjusted to 1,388,888 [2]. Group 2: Company Overview - INVO Fertility is focused on expanding assisted reproductive technology (ART) care, operating fertility clinics, and distributing its proprietary INVOcell medical device [4]. - The INVOcell device allows fertilization and early embryo development to occur in vivo, offering a more natural and cost-effective alternative to traditional IVF [4].

Core Insights - INVO Fertility, Inc. is enhancing its fertility services through expanded clinical and embryology training support and improved pricing for its INVOcell technology, aiming to provide patient-centered care while expanding clinic operations [1][3][4] Company Overview - INVO Fertility focuses on the fertility market, operating two INVO Centers and one IVF clinic in the U.S., and aims to build, acquire, and operate more fertility clinics [6] - The company offers the INVOcell, the first FDA-cleared intravaginal culture system, which allows fertilization and early embryo development to occur within a woman's body, providing a more natural alternative to traditional IVF [2][6] Product and Technology - INVOcell delivers comparable pregnancy rates to conventional IVF while offering a more intimate and affordable experience for patients [2][8] - The company has secured a notice of allowance for a new patent from the U.S. Patent and Trademark Office, reinforcing its position as a technology innovator [4] Training and Support - INVO Fertility provides hands-on training and clinical support for embryologists and physicians to integrate the INVOcell solution into their practices [3] - The company is launching targeted educational campaigns to raise awareness of patient success rates with INVOcell, which are similar to those of conventional IVF [3] Market Positioning - INVOcell is positioned as an inclusive option for diverse family structures, including same-sex couples and single parents, and offers a streamlined lab workflow for clinics [8]